Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome

McEvoy, 2005, Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III, Schizophr Res, 80, 19, 10.1016/j.schres.2005.07.014 Huang, 2009, Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan, Acta Psychiatr Scand, 120, 274, 10.1111/j.1600-0447.2009.01401.x Gardner-Sood, 2015, Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial, Psychol Med, 45, 2619, 10.1017/S0033291715000562 Deh, 2009, Metabolic syndrome in people with schizophrenia: a review, World Psychiatr, 8, 15, 10.1002/j.2051-5545.2009.tb00199.x Thakore, 2004, Metabolic disturbance in first-episode schizophrenia, Br J Psychiatr Suppl, 47, S76, 10.1192/bjp.184.47.s76 Vancampfort, 2015, Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis, World Psychiatr : official journal of the World Psychiatric Association, 14, 339, 10.1002/wps.20252 Baptista, 2008, Pharmacological management of atypical antipsychotic-induced weight gain, CNS Drugs, 22, 477, 10.2165/00023210-200822060-00003 Sakurai, 1998, Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior, Cell, 92, 573, 10.1016/S0092-8674(00)80949-6 Kastin, 1999, Orexin A but not orexin B rapidly enters brain from blood by simple diffusion, J Pharmacol Exp Therapeut, 289, 219 Messina, 2018, Functional changes induced by orexin A and adiponectin on the sympathetic/parasympathetic balance, Front Physiol, 9, 259, 10.3389/fphys.2018.00259 Shirasaka, 1999, Sympathetic and cardiovascular actions of orexins in conscious rats, Am J Physiol, 277, R1780 Messina, 2014, Orexin-A controls sympathetic activity and eating behavior, Front Psychol, 5, 997, 10.3389/fpsyg.2014.00997 Park, 2015, Orexin A regulates plasma insulin and leptin levels in a time-dependent manner following a glucose load in mice, Diabetologia, 58, 1542, 10.1007/s00125-015-3573-0 Tsuneki, 2015, Hypothalamic orexin prevents hepatic insulin resistance via daily bidirectional regulation of autonomic nervous system in mice, Diabetes, 64, 459, 10.2337/db14-0695 Strawn, 2010, Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder, Psychoneuroendocrinology, 35, 1001, 10.1016/j.psyneuen.2010.01.001 Steward, 2019, Reduced plasma orexin-A concentrations are associated with cognitive deficits in anorexia nervosa, Sci Rep, 9, 7910, 10.1038/s41598-019-44450-6 Lee, 2021, Differences in serum orexin-A levels between the acute and subacute withdrawal phases in individuals who use methamphetamine, Exp Clin Psychopharmacol, 29, 573, 10.1037/pha0000395 Tsuchimine, 2019, Reduced plasma orexin-A levels in patients with bipolar disorder, Neuropsychiatric Dis Treat, 15, 2221, 10.2147/NDT.S209023 Yamanaka, 2006, Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner, J Neurophysiol, 96, 284, 10.1152/jn.01361.2005 Linehan, 2019, Dopamine modulates excitatory transmission to orexin neurons in a receptor subtype-specific manner, Am J Physiol Regul Integr Comp Physiol, 316, R68, 10.1152/ajpregu.00150.2018 Chien, 2015, Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms, Psychoneuroendocrinology, 53, 1, 10.1016/j.psyneuen.2014.12.012 Chen, 2019, Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics, Int J Neuropsychopharmacol, 22, 28, 10.1093/ijnp/pyy075 Fadel, 2002, Differential activation of orexin neurons by antipsychotic drugs associated with weight gain, J Neurosci, 22, 6742, 10.1523/JNEUROSCI.22-15-06742.2002 Monda, 2008, Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A, Peptides, 29, 120, 10.1016/j.peptides.2007.10.016 Monda, 2003, Haloperidol reduces the sympathetic and thermogenic activation induced by orexin A, Neurosci Res, 45, 17, 10.1016/S0168-0102(02)00191-8 Monda, 2004, Clozapine blocks sympathetic and thermogenic reactions induced by orexin A in rat, Physiol Res, 53, 507, 10.33549/physiolres.930516 Monda, 2018, Functional changes of orexinergic reaction to psychoactive substances, Mol Neurobiol, 10.1007/s12035-017-0865-z Williams, 2020, Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies, Mol Psychiatr, 10.1038/s41380-020-0761-1 Lee, 1990, Reliability and validity of using a Brief psychiatric symptom rating Scale in clinical practice, J Formos Med Assoc, 89, 1081 Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 Pearson, 1909, Determination of the coefficient of correlation, Science, 30, 23, 10.1126/science.30.757.23 Dalal, 2003, Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects, Mol Psychiatr, 8, 836, 10.1038/sj.mp.4001363 Basoglu, 2010, Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis, Int Clin Psychopharmacol, 25, 165, 10.1097/YIC.0b013e3283377850 Messina, 2017, Role of autonomic nervous system and orexinergic system on adipose tissue, Front Physiol, 8, 137, 10.3389/fphys.2017.00137 Ahlenius, 1999, Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs, Pharmacol Toxicol, 84, 193, 10.1111/j.1600-0773.1999.tb01482.x Tuplin, 2017, Aripiprazole, A drug that displays partial agonism and functional selectivity, Curr Neuropharmacol, 15, 1192, 10.2174/1570159X15666170413115754 Sakurai, 2003, Orexin: a link between energy homeostasis and adaptive behaviour, Curr Opin Clin Nutr Metab Care, 6, 353, 10.1097/00075197-200307000-00001 Chieffi, 2017, Orexin system: the key for a healthy life, Front Physiol, 8, 10.3389/fphys.2017.00357